SCGB1A1 and cancer: Using our extensive pan-cancer NK cell atlas, we were able to generate a solely NK cell-derived, tissue-residency signature (atlas-TR: PSMA2, SLC5A3, CCL4L2, CLN3, SCGB1A1, AREG), which outperformed the conventional literature-derived TR signature across tissue and tumor type.